Key facts
- This page summarizes Eric R. Olson's Form 4 filing for Syros Pharmaceuticals, Inc. (SYRS).
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 17 Feb 2022, 15:08.
Eric R. Olson - 15 Feb 2022 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- SYRS
- Reported as of
- 15 Feb 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Feb 2022, 15:08:00 UTC
- Prior SEC filing
- 06 Jan 2022
- Next SEC filing
- 04 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Gerald E. Quirk, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric R. Olson filed Form 4 for Syros Pharmaceuticals, Inc. (SYRS) on 17 Feb 2022.
Change
- Previous filing in this sequence was filed on 06 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SYRS
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +100,000
- Change %
- Price
- $0.000000
- Shares after
- 100,000
- Date
- 15 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $1.59
- Footnotes
- F1
SYRS
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +80,000
- Change %
- Price
- $0.000000
- Shares after
- 80,000
- Date
- 15 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 80,000
- Exercise price
- Footnotes
- F2, F3
SYRS
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +200,000
- Change %
- Price
- $0.000000
- Shares after
- 200,000
- Date
- 15 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 200,000
- Exercise price
- Footnotes
- F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
This option becomes exercisable as to one quarter (1/4th) of the shares on February 28, 2023, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter.
Footnote F2
Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
Footnote F3
These RSUs will vest in four equal annual installments commencing on March 31, 2023.
Footnote F4
These RSUs will vest in full on March 31, 2025.